glp-1 short term use GLP-1s may reduce binge eating and similar behaviours in people living with obesity, suggests the most comprehensive systematic review and meta-analysis to date, published in eClinicalMedicine. Find out more 👉 http://spkl.io/61897yUsZ Figure GLP-1 Medications for Weight Loss:

Taking GLP-1s was particularly associated with a reduced risk of endometrial, ovarian and meningioma cancers

Diabetes Care 2011;34:818-22.PubMedPMC 60

Rybelsus According to StatPearls (NCBI), nearly one-fifth of patients taking Rybelsus in clinical trials experienced nausea as the most common side effect

The regulatory landscape is evolving: in February 2026, HHS announced that approximately 14 previously restricted peptides including BPC-157, TB-500, CJC-1295, Ipamorelin, and Sermorelin are expected to return to Category 1 compounding status

Together with insulin, amylin makes people feel full after eating a meal